2023
Effects of a high‐protein, increased‐fibre, dry diet supplemented with omega‐3 fatty acids on quality of life in dogs undergoing chemotherapy
Heinze C, Burgess K, Barber L, Rassnick K, Post G, Segaloff R, Bayle J. Effects of a high‐protein, increased‐fibre, dry diet supplemented with omega‐3 fatty acids on quality of life in dogs undergoing chemotherapy. Veterinary And Comparative Oncology 2023, 22: 2-11. PMID: 37933436, PMCID: PMC11115191, DOI: 10.1111/vco.12940.Peer-Reviewed Original ResearchQuality of lifeAdverse eventsFecal scoreGastrointestinal adverse eventsC-reactive proteinClient-owned dogsMulticenter clinical trialChemoattractant protein-1Mast cell tumorsFrequency of signsSignificant differencesCancer treatment optionsImpact of dietTest dietsQOL parametersCare chemotherapyLaboratory parametersPrimary outcomeOncology patientsFatty acidsLarge trialsMulticentric lymphomaQOL improvementTreatment optionsCell tumors
2015
202 KTN0158, a humanized anti-KIT monoclonal antibody, demonstrates antitumor activity in dogs with mast cell tumors
London C, Rippy S, Kisseberth W, Post G, Janson N, Crew L, LaVallee T, Gedrich R. 202 KTN0158, a humanized anti-KIT monoclonal antibody, demonstrates antitumor activity in dogs with mast cell tumors. European Journal Of Cancer 2015, 51: s27. DOI: 10.1016/s0959-8049(16)30090-9.Peer-Reviewed Original ResearchRecurrence rates and clinical outcome for dogs with grade II mast cell tumours with a low AgNOR count and Ki67 index treated with surgery alone
Smith J, Kiupel M, Farrelly J, Cohen R, Olmsted G, Kirpensteijn J, Brocks B, Post G. Recurrence rates and clinical outcome for dogs with grade II mast cell tumours with a low AgNOR count and Ki67 index treated with surgery alone. Veterinary And Comparative Oncology 2015, 15: 36-45. PMID: 25643820, DOI: 10.1111/vco.12140.Peer-Reviewed Original ResearchConceptsGrade II mast cell tumorsMast cell tumorsRecurrence rateLow proliferation activitySurgical excisionHistologic marginsKi67 indexCutaneous mast cell tumorsLow Ki67 indexLow AgNOR countsProliferation activityVariable biologic behaviorMedian followAncillary therapyDistant recurrenceLocal recurrenceClinical outcomesCell tumorsBiologic behaviorMast cellsAgNOR countsProliferation markersDogsRecurrenceTumors
2012
A Randomized Trial Investigating the Efficacy and Safety of Water Soluble Micellar Paclitaxel (Paccal Vet) for Treatment of Nonresectable Grade 2 or 3 Mast Cell Tumors in Dogs
Vail D, von Euler H, Rusk A, Barber L, Clifford C, Elmslie R, Fulton L, Hirschberger J, Klein M, London C, Martano M, McNiel E, Morris J, Northrup N, Phillips B, Polton G, Post G, Rosenberg M, Ruslander D, Sahora A, Siegel S, Thamm D, Westberg S, Winter J, Khanna C. A Randomized Trial Investigating the Efficacy and Safety of Water Soluble Micellar Paclitaxel (Paccal Vet) for Treatment of Nonresectable Grade 2 or 3 Mast Cell Tumors in Dogs. Journal Of Veterinary Internal Medicine 2012, 26: 598-607. PMID: 22390318, PMCID: PMC3837094, DOI: 10.1111/j.1939-1676.2012.00897.x.Peer-Reviewed Original ResearchConceptsMast cell tumorsAdverse eventsCell tumorsGrade 2Response ratePositive-controlled clinical trialMajority of AEsOverall response rateEarly phase studiesObserved response rateMechanism of actionAvailable TKIsPrimary endpointProspective multicenterSecondary endpointsSafety profileAE profileClinical trialsEffective treatmentPaclitaxel activityClinical importanceCombination protocolMicellar paclitaxelPaclitaxelLomustine
2005
A Phase I Clinical Trial Evaluating Imatinib Mesylate (Gleevec) in Tumor‐Bearing Cats
Lachowicz J, Post G, Brodsky E. A Phase I Clinical Trial Evaluating Imatinib Mesylate (Gleevec) in Tumor‐Bearing Cats. Journal Of Veterinary Internal Medicine 2005, 19: 860-864. PMID: 16355681, DOI: 10.1111/j.1939-1676.2005.tb02778.x.Peer-Reviewed Original ResearchConceptsPhase I clinical trialPO q24hImatinib mesylateClinical trialsSerum biochemistryMinimal gastrointestinal toxicityTumor-bearing catsTumor‐Bearing CatsDiagnosis of fibrosarcomaSquamous cell carcinomaTyrosine kinase inhibitorsMast cell tumorsSigns of toxicityAbdominal ultrasonographyConcurrent chemotherapyGastrointestinal toxicityDose escalationCell carcinomaCell tumorsThoracic radiographsQ24hRadiation therapyMost catsFurther evaluationKinase inhibitors
2001
Clinicopathologic and Electron Microscopic Study of Cutaneous Neuroendocrine (Merkel Cell) Carcinoma in a Cat with Comparisons to Human and Canine Tumors
Patnaik A, Post G, Erlandson R. Clinicopathologic and Electron Microscopic Study of Cutaneous Neuroendocrine (Merkel Cell) Carcinoma in a Cat with Comparisons to Human and Canine Tumors. Veterinary Pathology 2001, 38: 553-556. PMID: 11572564, DOI: 10.1354/vp.38-5-553.Peer-Reviewed Original ResearchConceptsMerkel cell tumorNeuroendocrine carcinomaCell tumorsMalignant neuroendocrine carcinomasCutaneous neuroendocrine carcinomaElectron microscopic findingsBasis of morphologicMaine Coon catsSurgical excisionMicroscopic findingsTumor malignancyCanine tumorsBenign natureTumorsMalignancyElectron microscopic studyCarcinomaCatsMicroscopic studyClinicopathologicHumansExcisionDiagnosisDogs